Monopar Therapeutics Inc ( (MNPR) ) has provided an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Monopar Therapeutics Inc. is advancing the fight against cancer with the initiation of a Phase 1a clinical trial for its innovative radiopharmaceutical therapy, MNPR-101-Lu, targeting advanced cancers. The therapy is designed to selectively attack cancer cells by focusing on the urokinase plasminogen activator receptor (uPAR), common in various tumor types. With promising clinical and preclinical data, Monopar is optimistic about this potential first-in-the-world uPAR-targeted treatment, aiming to improve outcomes with minimal harm to healthy tissue.
For an in-depth examination of MNPR stock, go to TipRanks’ Stock Analysis page.
